Regenxbio Inc (FRA:RB0)
€ 11.7 0.2 (1.72%) Market Cap: 582.38 Mil Enterprise Value: 351.37 Mil PE Ratio: 0 PB Ratio: 1.62 GF Score: 65/100

Regenxbio Inc at Barclays Global Healthcare Conference Transcript

Mar 17, 2022 / 02:45PM GMT
Release Date Price: €25.3 (+2.35%)
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Good morning, everyone. Welcome to Barclays Global Healthcare Conference. It is my -- this is Gena Wang, I cover SMid cap biotech. It is my great pleasure to introduce our -- at least in my session, last but not least, presenting company, REGENXBIO. With us today we have Ken Mills, President and Chief Executive Officer. We also have Steve Pakola, Chief Medical Officer. Ken, so maybe I will let you give a brief overview about the company, and then we dive into the Q&A.

Kenneth T. Mills
REGENXBIO Inc. - President, CEO & Director

Sounds great, Gena. Thanks to you and your team at Barclays for having us here. We're happy to be back in person. It's our first conference, at least at an investor level returning. So REGENXBIO is a gene therapy company. We are focused on AAV therapeutics as a platform. We've had a history in the field really for over 10 years since our formation. We've been a leader in pioneering the use of novel AAVs that were isolated in the lab of Jim Wilson at the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot